Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 2 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Recs

0
Player Avatar elica (< 20) Submitted: 2/18/2010 10:58:45 AM : Outperform Start Price: $32.20 ACOR Score: -49.61

great tech signs

Featured Broker Partners


Advertisement